Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in ...

Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...

Previous studies have identified TIM3 (T-cell immunoglobulin domain and mucin domain 3) as a negative regulator of T helper 1 (T H 1)-cell responses. Now, new research shows that TIM3 is also ...

anti-CD40L antibody frexalimab which is in mid-stage testing for multiple sclerosis, and SAR441566, an orally-active TNF blocker that Sanofi thinks could be the biggest drug it has ever developed.

Added to its challenges, Biogen is also seeing greater competitive pressures on its multiple sclerosis therapies Tecfidera ... Johnson's Remicade (infliximab) – all TNF inhibitors for rheumatoid ...

This progressive deterioration of immune competence alters key immunological functions, including dysregulation of inflammatory responses, impaired antimicrobial defenses, and heightened ...

In multiple sclerosis TNF-blocking drugs can promote onset or exacerbation of MS and GWAS (genome-wide association studies) data informed about the underlying mechanisms instructing clinical practice.

However, this apparent differential risk was due to more anakinra use (and avoidance of anti-TNF agents) in persons at high risk ... CR is the recipient of a postdoctoral fellowship from the Multiple ...

In traditional medicine, cardamom has been used to treat conditions like rheumatoid arthritis, multiple sclerosis, and psoriasis ... interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple ...

Updates in relapsing-remitting MS from AAN 2025 examine neurofilament light protein level as a prognostic biomarker, safety and efficacy of ofatumumab, and benefit of early initiation of ozanimod.

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple sclerosis (MS).